1alpha,25-Dihydroxyvitamin D3 Protects Dopaminergic Neurons in Rodent Models of Parkinson's Disease through Inhibition of Microglial Activation.
- Author:
Joong Seok KIM
1
;
Sun Young RYU
;
Injin YUN
;
Woo Jun KIM
;
Kwang Soo LEE
;
Jeong Wook PARK
;
Yeong In KIM
Author Information
- Publication Type:Original Article
- Keywords: Vitamin D; Parkinson's disease; 6-hydroxydopa (6-OHDA); 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP); Cytokine; Inflammation; Rat; Mouse
- MeSH: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Central Nervous System; Dopamine; Dopaminergic Neurons*; Inflammation; Mice; Microglia; Models, Animal; Neurons; Neuroprotective Agents; Parkinson Disease*; Rats; Rodentia*; Substantia Nigra; Vitamin D
- From:Journal of Clinical Neurology 2006;2(4):252-257
- CountryRepublic of Korea
- Language:English
- Abstract: BACKGROUND: Recent studies have demonstrated the molecular basis of the immunomodulatory and anti-inflammatory activities of 1,25-dihydroxyvitamin D3(1,25-(OH)2D3). This hormone improves behavioral deficits and normalizes the nigral dopamine levels in animal models of Parkinson's disease (PD). METHODS: We studied whether the administration of 1,25-(OH)2D3 would protect against 6-hydroxydopa (6-OHDA)- and 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced neuronal injury, and its potential regulatory effect on microglia activation. RESULTS: We found that 1,25-(OH)2D3 pretreatment significantly decreased 6-OHDA- and MPTP-induced dopaminergic neuronal loss in the substantia nigra pars compacta by preventing the activation of microglia. This observed neuroprotective effect in MPTP-treated mice that were given 1,25-(OH)2D3 may be attributable to inhibition of proinflammatory cytokine expression. CONCLUSION: These results suggest that 1,25-(OH)2D3 is a potentially valuable neuroprotective agent; it may therefore be considered for the treatment of pathologic conditions of the central nervous system, such as PD, where inflammation-induced neurodegeneration occurs.
